Health Trials

Muscular Invasive Bladder Cancer (MIBC)

2

Review clinical trials related to Muscular Invasive Bladder Cancer (MIBC). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).

Participants needed: 840
Trial details
Phase: Phase 2, Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Updated: Jul 13, 2026Locations: 1
Eligibility criteria

Received systemic anti-tumor therapy 4 weeks before starting the study treatment [+9]

Read more
Status: Recruiting

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).

Participants needed: 840
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Updated: Jun 18, 2025Locations: 1
Eligibility criteria

Age over 18 years old, gender not limited. [+6]

Received systemic anti-tumor therapy 4 weeks before starting the study treatment [+9]

Read more